Mon panier

FITC-Labeled Human CD8 alpha&beta (CD8A&CD8B) Heterodimer Protein, His Tag&Tag Free

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CDA-HF2W4-25ug
$330.00
CDA-HF2W4-200ug
$2245.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    CD8 alpha & beta, CD8A & CD8B

  • Source

    FITC-Labeled Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free (CDA-HF2W4) is expressed from human 293 cells (HEK293). It contains AA Ser 22 - Asp 182 (CD8A) & Leu 22 - Pro 170 (CD8B) (Accession # P01732-1 (CD8A) & P10966-1 (CD8B)). It is the FITC labeled form of Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free (Cat. No. CDA-H52W5).

    Predicted N-terminus: Ser 22 & Leu 22

    Request for sequence

  • Molecular Characterization

    CD8 alpha & beta Structure

    Other Tags and Version Biotin & Other Labeled Version

    FITC-Labeled Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free, produced by co-expression of CD8 alpha and CD8 beta, has a calculated MW of 19.5 kDa (CD8 alpha) and 22.1 kDa (CD8 beta). Subunit CD8 alpha is fused with a polyhistidine tag at the C-terminus and subunit CD8 beta contains no tag. The protein migrates as 30-32 kDa and 32-34 kDa under reducing (R) condition, and 30-33 kDa and 60-65 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Conjugate

    FITC

    Excitation source: 488 nm spectral line, argon-ion laser

    Excitation Wavelength: 488 nm

    Emission Wavelength: 535 nm

  • Labeling

    The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

  • Protein Ratio

    The FITC to protein molar ratio is 2.5-3.5.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    CD8 alpha & beta SDS-PAGE

    FITC-Labeled Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-ELISA

     CD8 alpha & beta ELISA

    Immobilized Anti-CD8 alpha Antibody, Mouse IgG2a (clone: OKT8) at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD8A&CD8B Heterodimer Protein, His Tag&Tag Free (Cat. No. CDA-HF2W4) with a linear range of 0.625-2.5 μg/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. CD8A forms disulfide-linked heterodimers with CD8B at the cell surface. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells. Additionally, CD8B plays a critical role in thymic selection of CD8+ T-cells. A palmitoylation site in the cytoplasmic tail of CD8B chain contributes to partitioning of CD8 into the plasma membrane lipid rafts where signaling proteins are enriched.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    T-cell surface glycoprotein CD8 beta chain

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    0 Détails

  • Étape de développement la plus élevée:

    Preclinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte